Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer

Anti-Cancer Drugs

Volumn 25, Issue 10, 2014, Pages 1201-1210

  Tang, Xiao Han ^a   Li, Meng ^a   Deng, Suo ^a   Lu, Mei Song ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cross reacting material 197; Drug resistance; Excision repair cross complementing group 1; Extracellular signal regulated kinase; Heparin binding epidermal growth factor like growth factor; Ovarian cancer

Indexed keywords

CISPLATIN; DIPHTHERIA TOXOID CRM197; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

A2780 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG MECHANISM; ENZYME INACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HUMANS; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84927759198     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000155     Document Type: Article

References (31)

1. Chengedza S, Benbrook DM. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs 2010; 21:297-305.
2. Eckstein N. Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res 2011; 30:91.
3. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64:5720-5727.
4. Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factorlike growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 2008; 7:3441-3451.
5. Tsujioka H, Yotsumoto F, Hikita S, Ueda T, Kuroki M, Miyamoto S. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Curr Opin Obstet Gynecol 2011; 23:24-30.
6. Suganuma K, Kubota T, Saikawa Y, Abe S, Otani Y, Furukawa T, et al. Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 2003; 94:355-359.
7. Fang L, Li G, Liu G, Lee SW, Aaronson SA. p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 2001; 20:1931-1939.
8. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 2007; 26:2006-2016.
9. Tang XH, Deng S, Li M, Lu MS. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer. Biochem Biophys Res Commun 2012; 422:676-680.
10. Lu M, Xiao L, Li Z. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci 2007; 27:725-728.
11. Tan W, Zhou W, Yu HG, Luo HS, Shen L. The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2013; 430:250-255.
12. Kanavaros P, Stefanaki K, Rontogianni D, Papalazarou D, Sgantzos M, Arvanitis D, et al. Immunohistochemical expression of p53, p21/waf1, rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus. Histol Histopathol 2001; 16:1005-1012.
13. Tsai MS, Weng SH, Chen HJ, Chiu YF, Huang YC, Tseng SC, et al. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide. Mol Cancer Ther 2012; 11:561-571.
14. Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F, Burdette JE. Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs 2011; 22:978-985.
15. Cha JH, Brooke JS, Eidels L. Toxin binding site of the diphtheria toxin receptor: loss and gain of diphtheria toxin binding of monkey and mouse heparin-binding, epidermal growth factor-like growth factor precursors by reciprocal site-directed mutagenesis. Mol Microbiol 1998; 29:1275-1284.
16. Zeng P, Wagoner HA, Pescovitz OH, Steinmetz R. RNA interference (RNAi) for extracellular signal-regulated kinase 1 (ERK1) alone is sufficient to suppress cell viability in ovarian cancer cells. Cancer Biol Ther 2005; 4:961-967.
17. Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E, et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One 2008; 3:e3894.
18. Abu-Yousif AO, Moor AC, Zheng X, Savellano MD, Yu W, Selbo PK, Hasan T. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett 2012; 321:120-127.
19. Jiao JW, Wen F. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatinresistant ovarian cancer cells. Oncol Rep 2011; 25:781-788.
20. Reed E, Dabholkar M, Thornton K, Thompson C, Yu JJ, Bostick-Bruton F. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep 2000; 7:1123-1128.
21. Li W, Melton DW. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 2012; 31:2412-2422.
22. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87:772-777.
23. Andrieux LO, Fautrel A, Bessard A, Guillouzo A, Baffet G, Langouët S. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 2007; 67:2114-2123.
24. Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, et al. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer. Clin Cancer Res 2008; 14:3149-3155.
25. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HBEGF, in ovarian cancer. Int J Cancer 2009; 124:1429-1439.
26. Miyamoto S, Yagi H, Tanaka Y. HB-EGF is a promising target molecule for ovarian cancer. Fukuoka Igaku Zasshi 2004; 95:286-290.
27. Hsu SC, Miller SA, Wang Y, Hung MC. Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res 2009; 1:249-258.
28. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003; 159:439-452.
29. Yoshida T, Okamoto I, Iwasa T, Fukuoka M, Nakagawa K. The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. FEBS Lett 2008; 582:4125-4130.
30. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, et al. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett 2013; 5:935-942.
31. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000; 60:1305-1313.